risankizumab · Skyrizi
Monoclonal antibody
Also known as BI 655066, ABBV-066
Evidence outlook
Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease (label: moderately to severely active CD or UC who have had an inadequate response to, lost response to, or...), Ulcerative Colitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (10)
- Moderately to severely active ulcerative colitis in adults
- Moderately to severely active Crohn's disease in adults
- Moderate to severe plaque psoriasis in adults (initial EU authorisation; PsA, Crohn's disease and ulcerative colitis added later)
- Moderately to severely active ulcerative colitis, induction and maintenance, where existing therapy is inadequate
- Moderately to severely active Crohn's disease (IV 600 mg and SC 360 mg autodoser) where existing therapy is inadequate
- Plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults with inadequate response to conventional therapies (first approval worldwide)
- Moderately to severely active Crohn's disease in adults
- Moderately to severely active Crohn's disease and ulcerative colitis
- Moderately to severely active Crohn's disease (authorised in Canada since October 2022, per Health Canada)
- Active psoriatic arthritis in adults (authorised in Canada since March 2022, per Health Canada)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02684370 NCT02684370 · Psoriasis This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16. Registry: NCT02684370 | 3 | Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A) 2016-12 | PASI90 at Week 16 (UltIMMa-1 trial, NCT02684370): risankizumab 75.3% vs placebo 4.9% vs ustekinumab 42.0% (p<0.0001 vs both comparators) | Reliable signal | link ↗ |
View 5 more trials
NCT02672852 NCT02672852 · Psoriasis This randomized, quadruple-blind, placebo-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on all three: 73.2% vs 2.0% achieving PASI90, and 83.5% vs 7.0% achieving clear-or-almost-clear skin at Week 16, plus better maintained clearance with continued treatment than withdrawal through Week 52. Registry: NCT02672852 | 3 | Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 (Baseline, Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16; Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 2017-08-02 | Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001 | Reliable signal | link ↗ |
OptIMMize-1 NCT04435600 · Psoriasis Most participants in this study received open-label risankizumab with no comparator, and even the cohort that also received ustekinumab was not blinded to participants or investigators; the registry reports response rates per cohort without a formal statistical test between groups. Registry: NCT04435600 | 3 | Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI) (Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)); Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) (At Week 16 of initial treatment in each part of the study (Parts 1-4)); Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline (Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)) 2024-02-12 | OptIMMize-1 (adolescents 12-<18y), Week 16: PASI75 85.2% (risankizumab) vs 85.7% (ustekinumab); PASI90 64.8% vs 60.7%; PASI100 40.7% vs 17.9%; sPGA0/1 79.6% vs 75.0%; sPGA0/1 with >=2-grade improvement 68.5% vs 67.9%. | Weak signal | link ↗ |
NCT02684357 NCT02684357 · Psoriasis The study was randomized and double-blind, used placebo and active ustekinumab comparators, and evaluated clinical psoriasis outcomes in 491 randomized participants; both primary Week 16 endpoints favored risankizumab with p<0.001. It is graded moderate because the provided record does not report a power calculation, so adequate powering cannot be confirmed despite the strong design and favorable results. Registry: NCT02684357 | 3 | Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A); Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A) 2016-12 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02694523 NCT02694523 · Psoriasis Randomized, double-blind, double-dummy trial against an active comparator (adalimumab) in 605 randomized patients, with skin clearance (PASI90 and physician global assessment) as the primary endpoints. Risankizumab was significantly better on every primary endpoint (p<0.001). The posted statistical analysis plan reports a power calculation of 300 patients per arm, and 301 and 304 were randomized. Registry: NCT02694523 | 3 | Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A); Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B) 2017-08 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
UnlIMMited NCT05969223 · Psoriasis Registry: NCT05969223 | 4 | Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16; Study-S: Percentage of Participants With Achievement of Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 16 2025-01-22 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (3)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other IL-23 p19 drugs
guselkumab, mirikizumab, tildrakizumab, HS-20137, JNJ-78934804 and 7 more. Compare all 13 IL-23 p19 drugs
This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Crohn's Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Risankizumab (Skyrizi): this drug | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1)) NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1)) | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | Partial signal | NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide (Entocort EC) | Approved | Small molecule | Glucocorticoid receptor | Weak signal | Featured results are safety only in this race | |
| Budesonide (Ortikos) | ApprovedUS marketing discontinued | — | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Weak signal | NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34) | |
| Dexamethasone | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02). | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin | |
| Infliximab-Dyyb (Zymfentra) | Approved | Monoclonal antibody | TNF-alpha | Reliable signal | No reviewed efficacy summary in this indication | |
| Infliximab-Qbtx (Ixifi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Methylprednisolone | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Mirikizumab (Omvoh) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab) | |
| Natalizumab (Tysabri) | Approved | Monoclonal antibody | α4 integrin | Partial signal | NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD) NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg) | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | Reliable signal | NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w) NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg)) | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Vedolizumab (Entyvio) | Approved | Monoclonal antibody | α4β7 integrin | Partial signal | NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC) NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed | |
| Afimkibart | Phase 3 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Duvakitug | Phase 3 | Monoclonal antibody | TL1A | Partial signal | NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. | |
| JNJ-78934804 | Phase 3 | Combination | IL-23 p19, TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Remestemcel-L (Ryoncil) | Phase 3 | Cell therapy | Allogeneic MSC therapy | Partial signal | No reviewed efficacy summary in this indication | |
| TH-SC01 | Phase 3 | Cell therapy | Mesenchymal stem cells (MSC) | Weak signal | No reviewed efficacy summary in this indication | |
| Tirzepatide (Zepbound) | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Tulisokibart | Phase 3 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Icotrokinra (Icotyde) | Phase 2/3 | Peptide | IL-23 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Amiselimod | Phase 2 | Small molecule | S1P receptor | Partial signal | NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed | |
| AVB-114 | Phase 2 | Cell therapy | Implantable cell/biomaterial construct | Partial signal | NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29). | |
| AZD7798 | Phase 2 | Monoclonal antibody | CCR9 | Weak signal | Featured results are safety only in this race | |
| ExoFlo | Phase 2 | Cell therapy | MSC-derived exosomes | Weak signal | Featured results are safety only in this race | |
| Golimumab (Simponi) | Phase 2 | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| MT-201 | Phase 2 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| MT-501 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Obefazimod | Phase 2 | Small molecule | miR-124 | not yet graded | No reviewed efficacy summary in this indication | |
| Omilancor | Phase 2 | Small molecule | LANCL2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zotemtegrast | Phase 2 | Small molecule | α4β7 integrin | not yet graded | No reviewed efficacy summary in this indication | |
| EcoActive | Phase 1/2 | Microbiome therapeutic | Bacteriophage (anti-AIEC) | not yet graded | No reviewed efficacy summary in this indication | |
| Furestem-CD | Phase 1/2 | Cell therapy | Allogeneic MSC therapy | Weak signal | No reviewed efficacy summary in this indication | |
| ICG318 | Phase 1/2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ALLO-ASC | Phase 1 | Cell therapy | Adipose-derived MSC therapy | Weak signal | No reviewed efficacy summary in this indication | |
| BDHK-2009 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Hemay007 | Phase 1 | Small molecule | TNF-alpha | Weak signal | No reviewed efficacy summary in this indication | |
| HRS-7085 | Phase 1 | Small molecule | NCBP1/NCBP2 (nuclear cap-binding complex) | Weak signal | No reviewed efficacy summary in this indication | |
| IPG11406 | Phase 1 | Small molecule | EBI2 | Weak signal | Featured results are safety only in this race | |
| LMT503 | Phase 1 | Small molecule | Macrophage polarization / Cellular metabolism | not yet graded | No reviewed efficacy summary in this indication | |
| OD-07656 | Phase 1 | Small molecule | RIPK2 | Weak signal | No reviewed efficacy summary in this indication | |
| TQH3906 | Phase 1 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 64 furthest-along competitors are listed; 7 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
6 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Skyrizi (risankizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (4)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (7)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
April 2028 (1)
What to watch
June 2028 (1)
What to watch
September 2028 (1)
What to watch
October 2028 (1)
What to watch
November 2028 (1)
What to watch
2029 (3)
February 2029 (1)
What to watch
April 2029 (1)
What to watch
August 2029 (1)
What to watch
2030 (2)
2031 (1)
October 2031 (1)
What to watch
2034 (1)
July 2034 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent